Genzyme Sues Seikagaku Over Synvisc-One Patent

Law360, New York (April 14, 2011, 5:47 PM EDT) -- Genzyme Corp. sued Seikagaku Corp. in Massachusetts on Thursday, claiming the Japanese pharmaceutical company's newly approved treatment for osteoarthritis knee pain infringes a patent for its knee pain relief treatment Synvisc-One.

The suit, filed in the U.S. District Court for the District of Massachusetts, alleges that Seikagaku's hyaluronic acid-based  Gel-One infringes U.S. Patent Number 5,399,351, titled "Biocompatible Viscoelastic Gel Slurries, Their Preparation and Use," issued March 21, 1995, by the U.S. Patent and Trademark Office.

Gel-One, a single-injection pain relief treatment, was approved March 22 by...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.